Immunohistochemical and FISH analysis of EGFR and its prognostic value in patients with oral squamous cell carcinoma

Journal of Oral Pathology and Medicine

Volumn 43, Issue 3, 2014, Pages 205-210

  Gröbe, Alexander ^a   Eichhorn, Wolfgang ^a   Fraederich, Meike ^a   Kluwe, Lan ^a   Vashist, Yogesh ^a   Wikner, Johannes ^a   Smeets, Ralf ^a   Simon, Ronald ^a   Sauter, Guido ^a   Heiland, Max ^a   Blessmann, Marco ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Epithelial growth factor receptor; Head and neck squamous cell carcinoma; Oral squamous cell carcinoma; Prognostic relevance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; EGFR PROTEIN, HUMAN;

ARTICLE; CLINICAL FEATURE; DISEASE SPECIFIC SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUTH CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; ADULT; AGED; CANCER GRADING; CANCER STAGING; CHEMISTRY; DISEASE FREE SURVIVAL; GENE AMPLIFICATION; GENETICS; HEAD AND NECK TUMOR; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY; PROCEDURES; SECONDARY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; YOUNG ADULT;

EID: 84896319323     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12111     Document Type: Article

References (31)

1. Silverman S Jr. Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. J Am Dent Assoc 2001; 132(Suppl): 7S-11S.
2. Gath HJ, Brakenhoff RH. Minimal residual disease in head and neck cancer. Cancer Metastasis Rev 1999; 18: 109-126.
3. Sano D, Myers JN. Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 2007; 26: 645-662.
4. Rosenthal DI, Harris J, Forastiere AA, et al. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. J Clin Oncol 2009; 27: 4727-4732.
5. Tagliabue E, Agresti R, Carcangiu ML, et al. Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 2003; 362: 527-533.
6. Rabinowits G, Haddad RI. Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncol 2012; 48: 1085-9.
7. Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11: 1873-8.
8. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78: 1284-92.
9. Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 2006; 94: 184-8.
10. Chiang WF, Liu SY, Yen CY, et al. Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinomas. Oral Oncol 2008; 44: 270-6.
11. Bettendorf O, Piffko J, Bankfalvi A. Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy? Oral Oncol 2004; 40: 110-119.
12. Markovic A, Chung CH. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma. Expert Rev Anticancer Ther 2012; 12: 1149-59.
13. Psyrri A, Yu Z, Weinberger PM, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005; 11: 5856-62.
14. Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 2005; 65: 338-48.
15. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824-32.
16. Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 2004; 58: 959-65.
17. Richter J, Wagner U, Kononen J, et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000; 157: 787-94.
18. Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999; 5: 1966-75.
19. Freier K, Joos S, Flechtenmacher C, et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 2003; 63: 1179-82.
20. Chandarana SP, Lee JS, Chanowski EJ, et al. Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer. Head Neck 2013; 35: 1083-90.
21. Hiraishi Y, Wada T, Nakatani K, Negoro K, Fujita S. Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas. Pathol Oncol Res 2006; 12: 87-91.
22. Diniz-Freitas M, Garcia-Caballero T, Antunez-Lopez J, Gandara-Rey JM, Garcia-Garcia A. Pharmacodiagnostic evaluation of EGFR expression in oral squamous cell carcinoma. Oral Dis 2007; 13: 285-90.
23. Rhodes A. Quality assurance in immunohistochemistry. Am J Surg Pathol 2003; 27: 1284-1285; author reply 1285-6.
24. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2-16.
25. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24: 4170-6.
26. Nagatsuka H, Ishiwari Y, Tsujigiwa H, Nakano K, Nagai N. Quantitation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malignant oral epithelial lesions. Oral Oncol 2001; 37: 599-604.
27. Takes RP, Baatenburg de Jong RJ, Schuuring E, Litvinov SV, Hermans J, Van Krieken JH. Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell. Anticancer Res 1998; 18: 4793-800.
28. Hanken H, Gröbe A, Cachovan G, et al. CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas. Clin Oral Investig 2013; [Epub ahead of print].
29. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25: 2164-2170.
30. Kong A, Leboucher P, Leek R, et al. Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Res 2006; 66: 2834-43.
31. Xia W, Lau YK, Zhang HZ, et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999; 5: 4164-74.